MX2021004650A - Composiciones para la eliminacion de celulas senescentes. - Google Patents

Composiciones para la eliminacion de celulas senescentes.

Info

Publication number
MX2021004650A
MX2021004650A MX2021004650A MX2021004650A MX2021004650A MX 2021004650 A MX2021004650 A MX 2021004650A MX 2021004650 A MX2021004650 A MX 2021004650A MX 2021004650 A MX2021004650 A MX 2021004650A MX 2021004650 A MX2021004650 A MX 2021004650A
Authority
MX
Mexico
Prior art keywords
senescent cells
elimination
compositions
cyclooxygenase
cox
Prior art date
Application number
MX2021004650A
Other languages
English (en)
Inventor
Johannes Grillari
Ingo Lämmermann
Vera Pils
Florian Gruber
Marie- Sophie NARZT
Original Assignee
Univ Wien Bodenkultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Bodenkultur filed Critical Univ Wien Bodenkultur
Publication of MX2021004650A publication Critical patent/MX2021004650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composición que comprende uno o más inhibidores capaces de inhibir al menos dos de ciclooxigenasa-1 (COX-1), ciclooxigenasa-2 (COX-2) y lipooxigenasa o una composición que comprende uno o más inhibidores capaces de inhibir una enzima con actividad de araquidonato-CoA ligasa, específicamente CoA ligasa de ácidos grasos de cadena larga (ACSL) 1, ACSL3, ACSL4, ACSL5, ACSL6, SLC27A2 o ACSBG2, o una combinación de los mismos para su uso en la eliminación selectiva de células senescentes. La invención se refiere además a un método in vitro para la identificación de células senescentes en un sujeto y se refiere a un método para identificar compuestos candidatos para la eliminación selectiva de células senescentes.
MX2021004650A 2018-10-25 2019-10-25 Composiciones para la eliminacion de celulas senescentes. MX2021004650A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18202657.5A EP3643305A1 (en) 2018-10-25 2018-10-25 Compositions for the elimination of senescent cells
PCT/EP2019/079133 WO2020084105A2 (en) 2018-10-25 2019-10-25 Compositions for the elimination of senescent cells

Publications (1)

Publication Number Publication Date
MX2021004650A true MX2021004650A (es) 2021-09-28

Family

ID=63998633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004650A MX2021004650A (es) 2018-10-25 2019-10-25 Composiciones para la eliminacion de celulas senescentes.

Country Status (12)

Country Link
US (1) US20210379087A1 (es)
EP (2) EP3643305A1 (es)
JP (2) JP2022505857A (es)
KR (1) KR20210100603A (es)
CN (1) CN113347969A (es)
AU (1) AU2019365405A1 (es)
BR (1) BR112021007815A2 (es)
CA (1) CA3117553A1 (es)
IL (1) IL282596A (es)
MX (1) MX2021004650A (es)
SG (1) SG11202103736UA (es)
WO (1) WO2020084105A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110934873B (zh) * 2019-08-22 2022-10-28 中国科学院上海营养与健康研究所 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
AU2021283886A1 (en) * 2020-06-02 2023-01-19 Buck Institute For Research On Aging Dihomo-gamma linolenic acid (DGLA) is a novel senolytic
EP4168130A1 (en) * 2020-06-19 2023-04-26 Unilever IP Holdings B.V. Use of indole compounds for treating signs of skin aging
WO2022204519A1 (en) 2021-03-26 2022-09-29 The United States Government As Represented By The Department Of Veterans Affairs Use of zt-1a and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders
WO2022232110A1 (en) * 2021-04-26 2022-11-03 Jem Therapeutics Pbc Method of treatment for autophagy diseases by administration of dexibuprofen and use of dexibuprofen for preparation of a medicament for same
CN113730409B (zh) * 2021-11-01 2022-06-14 济南市中心医院 奎纳克林在制备治疗肺纤维化药物中的应用
WO2023085787A1 (ko) * 2021-11-10 2023-05-19 주식회사 라이프신약 노화세포 제거용 조성물 및 이의 용도
WO2023090901A1 (ko) * 2021-11-18 2023-05-25 의료법인 성광의료재단 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법
CN114404397B (zh) * 2022-01-29 2023-04-25 北京大学口腔医学院 用于防治骨质疏松或骨吸收的3-溴丙酮酸制剂及其应用
TWI818466B (zh) * 2022-03-15 2023-10-11 高雄醫學大學 用於治療砷誘發之肺功能損傷之類黃酮藥物
CN115137717A (zh) * 2022-06-08 2022-10-04 深圳先进技术研究院 双硫仑药物在治疗骨关节炎中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073505A1 (es) * 2009-09-10 2010-11-10 Monte Verde S A Composiciones y metodos para el tratamiento de enfermedades proliferativas
US20170216286A1 (en) * 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
WO2019070407A1 (en) 2017-10-06 2019-04-11 Buck Institute For Research On Aging BIOMARKER FOR SENESCENT CELLS

Also Published As

Publication number Publication date
BR112021007815A2 (pt) 2021-09-08
EP3870164A2 (en) 2021-09-01
WO2020084105A2 (en) 2020-04-30
JP2022505857A (ja) 2022-01-14
AU2019365405A1 (en) 2021-05-20
EP3643305A1 (en) 2020-04-29
WO2020084105A3 (en) 2020-08-06
CA3117553A1 (en) 2020-04-30
IL282596A (en) 2021-06-30
US20210379087A1 (en) 2021-12-09
JP2024012402A (ja) 2024-01-30
KR20210100603A (ko) 2021-08-17
CN113347969A (zh) 2021-09-03
SG11202103736UA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
MX2021004650A (es) Composiciones para la eliminacion de celulas senescentes.
MX2018013224A (es) Número de objetivo por amplificación de discordancias optimizada multiplicada (moma).
CR20210013A (es) Inhibidores de pd-1/pd-l1
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2018011105A (es) Inhibidores sustituidos de menina-mll y metodos de uso.
CR20200347A (es) Inhibidores pd-1/pd-l1
EP3873468A4 (en) 2-AMINO-N-PHENYL-NICOTINAMIDE USED AS NAV1.8 INHIBITORS
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12018501656A1 (en) Methods for using fxr agonists
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
MX2018000471A (es) Moduladores de proteolisis basados en alanina y metodos de uso asociados.
WO2018017368A9 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GUT OR HYPERURICEMIA
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
PH12020550556A1 (en) Novel combinations of defoliants
NZ728484A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
MX2018013261A (es) Reacción de cadena de polimerasas para amplificación de discordancias optimizada multiplicada (moma)-en tiempo real para la valoración del bienestar fetal.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
NZ726907A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
MX2017008450A (es) Composiciones inhibidoras de nitrificacion microencapsuladas.
EP3677126A4 (en) COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION
WO2019039817A3 (ko) 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
MX2020001557A (es) Combinaciones herbicidas sinergicas.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.